4Z7 Stock Overview IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
IRRAS AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for IRRAS Historical stock prices Current Share Price US$0.013 52 Week High US$0.041 52 Week Low US$0.01 Beta 0 1 Month Change 0% 3 Month Change 3.15% 1 Year Change -66.41% 3 Year Change -98.10% 5 Year Change n/a Change since IPO -97.88%
Recent News & Updates
IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm Oct 21 IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting Oct 20
Insufficient new directors Sep 29 Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS). Sep 05
IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023 Jul 04 IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024 See more updates
IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm Oct 21 IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting Oct 20
Insufficient new directors Sep 29 Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS). Sep 05
IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023 Jul 04 IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024
IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member Jun 02
First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022) May 18
Insufficient new directors May 11
Insufficient new directors Feb 23
Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021) Feb 18
IRRAS AB (publ) Announces That the Publication of the First Comparative Study Feb 13 IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024
Insufficient new directors Dec 17
IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit Dec 12
Insufficient new directors Nov 21
IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity Nov 18
IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023 Nov 11
Insufficient new directors Sep 07 IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million. Aug 25
Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study Aug 23
Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021) Jul 23
IRRAS AB Provides Revenue Guidance for the Year 2022 Jul 05
Insufficient new directors Jun 02
IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System Mar 05
IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States Feb 22
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 17 IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022
IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system Feb 10
IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage Jan 30
Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020) Nov 10
IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open Oct 01
Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020) Aug 28
IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications Jul 23
IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage May 28
First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020) May 05
Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations Mar 10
New 90-day low: €0.62 Feb 18
Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019) Feb 18
Revenue misses expectations Feb 18
Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions Dec 18
IRRAS AB Announces Exclusive Distribution Agreement with Anade SA Dec 10
New 90-day high: €0.81 Dec 10
IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV Nov 26
IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products Nov 17
Revenue misses expectations Nov 11
Third quarter 2020 earnings released: kr0.47 loss per share Nov 11
New 90-day high: €0.66 Sep 28
First half earnings released Aug 29 Shareholder Returns 4Z7 DE Medical Equipment DE Market 7D 0% 1.0% 1.7% 1Y -66.4% -8.3% 9.4%
See full shareholder returns
Return vs Market: 4Z7 underperformed the German Market which returned 0.4% over the past year.
Price Volatility Is 4Z7's price volatile compared to industry and market? 4Z7 volatility 4Z7 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4Z7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4Z7's volatility change over the past year.
About the Company IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma.
Show more IRRAS AB (publ) Fundamentals Summary How do IRRAS's earnings and revenue compare to its market cap? 4Z7 fundamental statistics Market cap €167.97m Earnings (TTM ) -€196.40m Revenue (TTM ) €43.10m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4Z7 income statement (TTM ) Revenue SEK 43.10m Cost of Revenue SEK 44.03m Gross Profit -SEK 935.00k Other Expenses SEK 195.47m Earnings -SEK 196.40m
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 21, 2024
Earnings per share (EPS) -0.17 Gross Margin -2.17% Net Profit Margin -455.71% Debt/Equity Ratio 0%
How did 4Z7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/31 15:55 End of Day Share Price 2023/11/03 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IRRAS AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sten Gustafsson ABG Sundal Collier Kristofer Liljeberg-Svensson Carnegie Investment Bank AB Christian Lee Pareto Securities
Show 1 more analysts 
